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Knee arthroplastyAbstract Background: Epidural analgesia is still the preferred method of postoperative analgesia
for total knee arthroplasty in many countries. Dexmedetomidine is a new alpha-2 agonist which had
many beneficial effects when administered epidurally. The aim of study was to provide effective
postoperative analgesia with hemodynamic stability through reduction of the amount of epidural
local anesthetic by adding dexmedetomidine.
Methods: 75 patients, 50–70 years old, ASA physical status I–III undergoing total knee arthro-
plasty were randomly divided into three equal groups, group I received 0.125% bupivacaine
5 ml/h for postoperative analgesia, group II received 4 ml of a mixture of bupivacaine 0.125%
and dexmedetomidine 0.2 lg/kg/h and group III received 3 ml of a mixture of bupivacaine
0.125% and dexmedetomidine 0.2 lg/kg/h. Postoperative pain were scored by visual analog scale
(VAS), sedation score, postoperative nalbuphine consumption and hemodynamic parameters were
recorded every 4 h for 48 h postoperatively.
Results: The demographic data were comparable in all groups. VAS (visual analog scale) of pain
showed a significant reduction between the two groups II, III and group I with insignificant differ-
ence between groups II and III at both rest and movement. The mean of nalbuphine consumption
during the study period was significantly reduced in group II, III than in group I with insignificant
difference between groups II and III. Sedation scores were significantly higher in groups II and III
compared to group I. Heart rate was more reduced in groups II and III than in group I with
insignificant difference between the groups. The mean arterial blood pressure was significantly
reduced in group I than groups II and III from hour 8 till the end of the study.
Conclusion: Dexmedetomidine is an effective adjuvant to epidural bupivacaine for postoperative
analgesia after total knee arthroplasty through reducing the amount of local anesthetic.
 2016 Publishing services by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).lkoom,
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Total knee arthroplasty is associated with sever early postop-
erative pain which remains the major factor that limits patients
seeking TKA [1]. Improving the pain management techniques
has significant impact on stress response and postoperative
outcome [2,3]. The use of epidural analgesia is the preferred
technique of analgesia in many European countries for total
knee arthroplasty, as revealed by a declarative European sur-
vey [4]. Epidural techniques are commonly used in postopera-
tive analgesia for elderly patients, with the combination of a
local anesthetic and an opioid being preferred [5,6]. However,
the occurrence of serious adverse effects (eg, hypotension, res-
piratory depression, deep bradycardia) and unwanted adverse
events (eg, nausea, vomiting, motor block) with these analgesic
regimens make it necessary to continue research about differ-
ent and more optimal analgesia methods [6,7]. The a-2 ago-
nists, particularly the combination of clonidine with local
anesthetics administered via the epidural or spinal route, have
been found to be effective in pain management [8–10].
Dexmedetomidine, another a-2 receptor agonist, is firstly used
in ICUs for sedation of patients [11–13]. The effective analge-
sia obtained with dexmedetomidine has been widely discussed
[14–16]. However, clinical studies on its spinal and epidural use
are limited, also it has got numerous beneficial effects when
used epidurally [17].
Hence, in the present study we have hypothesised that add-
ing epidural adjunct dexmedetomidine to low volumes of bupi-
vacaine, aiming to reduce the complications of epidural local
anesthetics and opioids, and provide suitable postoperative
analgesia for patients undergoing total knee arthroplasty with-
out hemodynamic instability.
2. Materials and methods
After approval of the institutional ethics committee and Pan
African Clinical Trial Registry (www.pactr.org) PACTR
201503001068335. Written consents of 75 patients, 50–70 years
old, American Society of Anesthesiology (ASA) physical status
I–III, admitted to Menoufiya University Hospitals, undergo-
ing elective total knee arthroplasty were included in this
prospective, double-blinded, randomized controlled study.
Exclusion criteria included morbid obese, age older than
70 years, known allergy to bupivacaine or dexmedetomidine,
renal or hepatic insufficiency, cardiac conduction disturbances,
neurological or psychiatric diseases and coagulation disorders.
Patients were randomly classified into three parallel groups (20
patients in each group) using closed envelope technique. A
good intravenous line was accessed by 18 gauge intravenous
cannula and Ringer’s solution infused at a rate of 6–15 ml/
kg/hour. All patients received midazolam 2 mg IV five minutes
before epidural anesthesia was performed. Routine monitoring
was applied pre-operatively including ECG, NIBP and pulse
oximetry and the baseline measurements were recorded. A
combined spinal and epidural technique was used for anesthe-
sia and postoperative analgesia. A 16 G Tuohy needle was
used to insert an epidural catheter at the L3–4 or L4–5 inter-
spaces. In all patients, a midline approach was used, with the
epidural space identified using loss of resistance then the epidu-
ral catheter was introduced into epidural space for 3–4 cm anda test dose of 2 ml of lidocaine 2% containing adrenaline
1:200,000 was given to exclude both intrathecal and intra-
venous injection. Then spinal anesthesia was given by 15 mg
0.5% heavy bupivacaine. Patients in group I (control group)
received only 5 ml/h of bupivacaine 0.125%, group II received
4 ml/h of a mixture of bupivacaine 0.125% and dexmedeto-
midine 0.2 lg/kg/h and group III received 3 ml/h of a mixture
of bupivacaine 0.125% and dexmedetomidine 0.2 lg/kg/h.
Post-operative pain scores were assessed using a 10 cm visual
analog scale (VAS) (0 = no pain and 10 = worst pain
imaginable) during rest (primary outcome) and movement
(secondary outcome). According to the patient’s request to
analgesia when VASP 4, post-operative incremental doses
of I.V. 4 mg nalbuphine were given and recorded. The patient’s
level of sedation was assessed using the inverted observer’s
assessment of alertness/sedation scale [18], with a score of
1 = completely awake, 2 = awake but drowsy, 3 = asleep
but responsive to verbal commands, 4 = asleep but responsive
to tactile stimulus, and 5 = asleep and not responsive to any
stimuli. The post-operative data (e.g. pain, sedation) and
cardio-respiratory parameters (heart rate, blood pressure and
SpO2) were monitored and recorded every 4 h for 48 h.
2.1. Statistical analysis
A power analysis was performed using a power of 85% and an
a value 0.05. We assumed that the minimum difference of pain
scores at rest (primary outcome of the study) was 20% and
standard deviation 20%. The sample size was calculated to
be 23 patients so we decided to include 25 patients in each
group in the study. We used GraphPad Stat Mate version 2
statistics program for power analysis.
Statistical analysis was done using SPSS program.
Descriptive statistics were expressed as mean + SD unless
otherwise stated. One way analysis of variance (ANOVA) with
Student Newman–Keuls post-hoc test was used for compar-
ison of the means of continuous variables and normally
distributed data. The Chi-square test was used otherwise.
P-value < 0.05 was considered statistically significant.
3. Results
The demographic data of the patients in the three groups
were comparable with regards to age, sex, weight and height
(Table 1). During the course of the study, VAS (visual analog
scale) of pain at rest showed a significant reduction between
group I and both groups II and III with insignificant difference
between groups II and III at rest during the first 24 h and
insignificant reduction between the studied groups during the
rest of the study (Table 2), while VAS of pain at movement,
showed significant reduction between group I and the other
2 group with insignificant difference between groups II and
III all over the study period (Table 3). The mean of nalbuphine
consumption during the study period was significantly reduced
in group II and group III more than in group I with insignif-
icant difference between groups II and III (Table 4). The seda-
tion score was significantly higher in groups II and III (which
received dexmedetomidine) compared to group I with insignif-
icant difference between the two groups II and III (Table 5).
Whereas heart rate was reduced in both groups II, III used
Table 1 Demographic data.
Character Group I Group II Group III P-value
Age (years) 58.88 ± 4.77 60.2 ± 3.89 59.12 ± 4.87 0.55
Sex (F/M) 14/11 13/12 10/15 0.5
Weight (kg) 86.64 ± 6.82 86.16 ± 6.99 85.76 ± 6.53 0.9
Height (cm) 159.08 ± 6.99 161 ± 6.89 163.12 ± 8.83 0.18
Group I: Bupivacaine (5 ml/h), Group II: Dexmeditomidine + 4 ml/h bupivacaine, Group III: Dexmeditomidine + 3 ml/h bupivacaine, F:
Female, and M: Male.
Data were expressed as mean ± SD and number of patients.
Table 2 VAS at rest.
Time (h) Group I Group II Group III P-value
4 4.2 ± 2.15*y 2.5 ± 1.4 2.6 ± 1.3 <0.001
8 3.48 ± 1.45 2.3 ± 1.6 2.4 ± 1.5 0.009
12 3.04 ± 1.1*y 2.05 ± 1.14 2.07 ± 1.13 0.003
16 2.85 ± 0.91*y 1.87 ± 1.0 1.89 ± 1.1 <0.001
20 2.77 ± 0.85*y 1.77 ± 0.98 1.8 ± 1.0 <0.001
24 2.68 ± 0.76 2.15 ± 0.84 2.16 ± 0.85 0.038
28 2.46 ± 0.83 2.16 ± 0.76 2.18 ± 0.87 0.358
32 2.43 ± 0.81 2.13 ± 0.74 2.16 ± 0.75 0.320
36 2.4 ± 0.87 2.11 ± 0.72 2.13 ± 0.73 0.342
40 2.39 ± 0.89 1.99 ± 0.9 2.1 ± 0.72 0.228
44 2.36 ± 0.91 1.94 ± 0.8 1.92 ± 0.7 0.101
48 2.34 ± 0.81 1.87 ± 0.75 1.88 ± 0.73 0.052
Group I: Bupivacaine (5 ml/h), Group II: Dexmeditomidine +
4 ml/h bupivacaine, Group III: Dexmeditomidine + 3 ml/h
bupivacaine.
Data were expressed as mean ± SD.
* Significance between group I and group II.
y Significance between group I and group III.
Table 3 VAS at movement.
Time (h) Group I Group II Group III P-value
4 5.08 ± 1.41*y 4.11 ± 1.36 4.14 ± 1.38 0.023
8 4.92 ± 1.29*y 3.88 ± 0.98 4.04 ± 1.27 0.006
12 4.76 ± 1.3*y 3.82 ± 0.97 3.84 ± 0.99 0.004
16 4.7 ± 1.36*y 3.68 ± 0.86 3.72 ± 0.94 0.001
20 4.6 ± 1.35*y 3.6 ± 0.88 3.65 ± 0.86 0.001
24 4.32 ± 1.28*y 3.52 ± 0.76 3.48 ± 0.77 0.004
28 4.12 ± 1.09*y 3.2 ± 0.74 3.4 ± 0.79 0.001
32 3.98 ± 1.03*y 3.15 ± 0.75 3.36 ± 0.81 0.003
36 3.88 ± 0.97*y 3.1 ± 0.74 3.16 ± 0.75 0.002
40 3.68 ± 0.85*y 3.09 ± 0.77 3.1 ± 0.73 0.013
44 3.54 ± 0.73*y 3.02 ± 0.72 3.08 ± 0.76 0.029
48 3.36 ± 0.64*y 2.66 ± 0.7 2.76 ± 0.6 <0.001
Group I: Bupivacaine (5 ml/h), Group II: Dexmeditomidine +
4 ml/h bupivacaine, Group III: Dexmeditomidine + 3 ml/h
bupivacaine.
Data were expressed as mean ± SD.
* Significance between group I and group II.
y Significance between group I and group III.
Table 4 Nalbuphine consumption.
Time (h) Group I Group II Group III P-value
4 3.76 ± 0.66*y 2.96 ± 1.02 3.2 ± 1.0 0.008
8 3.6 ± 0.82*y 2.88 ± 1.01 3.04 ± 1.02 0.024
12 3.28 ± 0.98*y 2.56 ± 0.92 2.72 ± 0.98 0.025
16 2.8 ± 1.0*y 2.16 ± 0.55 2.32 ± 0.75 0.015
20 2.48 ± 0.87*y 1.84 ± 0.55 2.0 ± 0.58 0.004
24 3.38 ± 0.95*y 2.64 ± 0.95 2.8 ± 1.0 0.021
28 3.12 ± 1.01*y 2.4 ± 0.82 2.56 ± 0.92 0.018
32 3.04 ± 1.02*y 2.32 ± 0.75 2.48 ± 0.87 0.014
36 2.8 ± 1.0*y 2.16 ± 0.55 2.32 ± 0.75 0.015
40 2.48 ± 0.87*y 1.84 ± 0.55 2.0 ± 0.58 0.004
44 2.4 ± 0.82*y 1.76 ± 0.66 1.92 ± 0.4 0.002
48 2.56 ± 0.92*y 1.92 ± 0.4 2.08 ± 0.4 0.001
Group I: Bupivacaine (5 ml/h), Group II: Dexmeditomidine +
4 ml/h bupivacaine, Group III: Dexmeditomidine + 3 ml/h
bupivacaine.
Data were expressed as mean ± SD.
* Significance between group I and group II.
y Significance between group I and group III.
Table 5 Sedation score.
Time (h) Group I Group II Group III P-value
4 1.27 ± 0.45 1.54 ± 0.73 1.52 ± 0.7 0.257
8 1.28 ± 0.46*y 1.72 ± 0.68 1.7 ± 0.66 0.019
12 1.3 ± 0.47*y 1.79 ± 0.83 1.78 ± 0.77 0.024
16 1.32 ± 0.48*y 1.88 ± 0.83 1.87 ± 0.82 0.011
20 1.24 ± 0.44*y 1.78 ± 0.85 1.78 ± 0.84 0.014
24 1.21 ± 0.42*y 1.69 ± 0.81 1.68 ± 0.79 0.025
28 1.13 ± 0.34*y 1.67 ± 0.77 1.65 ± 0.75 0.006
32 1.14 ± 0.35*y 1.68 ± 0.8 1.69 ± 0.9 0.012
36 1.17 ± 0.37*y 1.76 ± 0.88 1.77 ± 0.89 0.008
40 1.18 ± 0.38*y 1.88 ± 0.93 1.86 ± 0.92 0.003
44 1.12 ± 0.33*y 1.68 ± 0.8 1.66 ± 0.7 0.004
48 1.07 ± 0.27*y 1.42 ± 0.41 1.41 ± 0.39 0.001
Group I: Bupivacaine (5 ml/h), Group II: Dexmeditomidine +
4 ml/h bupivacaine, Group III: Dexmeditomidine + 3 ml/h
bupivacaine.
Data were expressed as mean ± SD.
* Significance between group I and group II.
y Significance between group I and group III.
Dose reduction study of local anesthetic on postoperative epidural analgesia 367dexmedetomidine more than in bupivacaine group I, there was
no significant difference between the three groups and none of
the heart rate values were found to be outside the normal range
(Table 6). On contrast, the mean arterial blood pressure was
significantly reduced in group I than groups II, III with signif-icant difference between group II and group III from hour 8
till the end of the study (Table 5). There was insignificant dif-
ference between the two groups in relation to SpO2 (see
Table 7).
Table 6 Heart rate.
Time (h) Group I Group II Group III P-value
Base 77.08 ± 8.65 77.52 ± 9.28 72.24 ± 9.37 0.082
4 76.2 ± 8.63 76.56 ± 9.15 76.52 ± 8.94 0.988
8 75.92 ± 8.8 75.64 ± 8.3 75.88 ± 8.6 0.992
12 75.2 ± 8.54 75.08 ± 7.68 74.88 ± 8.09 0.990
16 74.52 ± 8.21 73.96 ± 6.62 74.2 ± 7.8 0.966
20 74.08 ± 7.6 73.32 ± 5.71 72.84 ± 6.87 0.809
24 73.88 ± 5.62 73.64 ± 7.48 73.16 ± 6.9 0.928
28 74.24 ± 5.67 72.16 ± 6.2 73.36 ± 6.82 0.501
32 72.44 ± 6.1 774.4 ± 5.61 73.04 ± 6.75 0.521
36 73.84 ± 5.34 71.2 ± 5.22 72.6 ± 6.45 0.267
40 73.12 ± 5.29 70.36 ± 4.38 70.4 ± 4.41 0.066
44 72.36 ± 5.01 70.92 ± 3.91 70.92 ± 4.11 0.409
48 72.68 ± 5.97 71.72 ± 3.9 71.56 ± 4.14 0.669
Group I: Bupivacaine (5 ml/h), Group II: Dexmeditomidine +
4 ml/h bupivacaine, Group III: Dexmeditomidine + 3 ml/h
bupivacaine.
Data were expressed as mean ± SD.
Table 7 Mean arterial blood pressure.
Time (h) Group I Group II Group III P-value
Base 97.92 ± 8.11 93 ± 6.89 94.88 ± 10.42 0.132
4 92.4 ± 7.97 90.27 ± 4.26 91.08 ± 6.93 0.516
8 82.44 ± 5.9*y 85.45 ± 5.01 88.96 ± 8 0.003
12 80.92 ± 3.35*y 85.1 ± 4.49 88.6 ± 8.01 <0.001
16 80 ± 3.43*y 85 ± 4.38 88.2 ± 5.79 <0.001
20 77.88 ± 4.3*y 82.6 ± 4.73 86.16 ± 5.25 <0.001
24 76 ± 4.69*y 82.2 ± 4.69 86.6 ± 5.19 <0.001
28 76.56 ± 4.79*y 82.5 ± 5.02 87.12 ± 5.09 <0.001
32 77.04 ± 5.02*y 83.2 ± 5.23 87.68 ± 5.03 <0.001
36 79.04 ± 4.12*y 84.09 ± 4.23 88.52 ± 4.91 <0.001
40 81.2 ± 4.69*y 85.32 ± 5.3 89.24 ± 4.64 <0.001
44 83.08 ± 4.13*y 86.01 ± 5.35 90.28 ± 4.27 <0.001
48 84.76 ± 5.64*y 87.88 ± 4.97 91.68 ± 4.47 <0.001
Group I: Bupivacaine (5 ml/h), Group II: Dexmeditomidine +
4 ml/h bupivacaine, Group III: Dexmeditomidine + 3 ml/h
bupivacaine.
Data were expressed as mean ± SD.
* Significance between group I and group II.
y Significance between group I and group III.
 Significance between group II and group III.
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The present study has found that adding dexmedetomidine as
an adjuvant to postoperative epidural bupivacaine 0.125% in
patients undergoing total knee replacement significantly
reduced local anesthetic volume from 5 ml/h to 3 ml/h
(40%), postoperative pain during both rest and movement,
with significant reduction in postoperative nalbuphine con-
sumption and cardiorespiratory stability.
Total knee arthroplasty (TKA) is a successful procedure to
improve the quality of life in patients with degenerative joint
disease [19]. Severe postoperative pain is a significant concern
for patients and can affect the physiological, psychological sta-
tus and clinical outcomes of these patients. Most of the candi-
dates for TKA are elderly and have medical comorbidities that
can worsen when subjected to stress. As a result, postoperativepain management has become an essential part of the periop-
erative care program for TKA [20,21].
Epidural analgesia is the most commonly recommended
method for postoperative pain management of this age group
[5]. However, choosing the optimal epidural drug is still the
subject of many investigations [5,22]. Using only local anes-
thetics at effective doses raises concerns about adverse events,
such as hypotension, bradycardia, motor weakness, and eleva-
tion in block level [22]. Opioid combinations may not provide
satisfactory results, as they are associated with respiratory
depression, nausea, vomiting and pruritus [6,22]. Dexmedeto-
midine is a new opioid-sparing adjuvant to epidural adminis-
tration. Dexmedetomidine is a potent and highly selective
a2-adrenoceptor agonist [23]. This causes it to be a much more
effective sedative and analgesic agent, with much less
unwanted cardiovascular effects [24]. It acts on both pre and
post-synaptic sympathetic nerve terminal and central nervous
system thereby decreasing the sympathetic outflow and nore-
pinephrine release causing sedative, anti-anxiety, analgesic,
sympatholytic and hemodynamic effects [17,25].
In the present study epidural dexmedetomidine groups
reduced postoperative VAS at rest and movement as found
by Elhakim and colleagues [24] and also decreased post-
operative analgesic (nalbuphine) requirement as was expected
in the view of the established analgesic efficacy of dexmedeto-
midine and other centrally acting a-2 agonists [17,24,25].
Dexmedetomidine has a potent sedative effect which approved
by the present study, that showed a significant increase of seda-
tion score in dexmedetomidine groups. The sedative and anal-
gesic effects of dexmedetomidine has been documented in
several studies [26–28], after major surgical surgeries [29], after
thoracic surgery [24], after vaginal hysterectomy [17] and after
lower limb orthopadic surgery [29]. Dexmedetomidine exerts
its sedative and analgesic sparing effects through central
actions in the locus coeruleus and in the dorsal horn of the
spinal cord, respectively [30,31]. In the present study, mean
HR was insignificantly lower in the dexmedetomidine groups
II, III than bupivacaine group I as expected in many studies
[17,24,31] and remained within normal limits, as reported in
other studies [32–34], which was an advantage in these geriatric
patients. The decrease in heart rate caused by a-2 agonist can
be explained by their central action decreasing the sympathetic
outflow and norepinephrine release [35]. In contrast to heart
rate results, the mean arterial pressure was significantly
decreased in bupivacaine group I than the two groups II, III
in which patients received dexmedetomidine with significant
decrease in group II than group III which can be explained
by using lower volume of local anesthetic in group III (3 ml/
h) than used in group I (5 ml/h) and in group II (4 ml/h).
Although there was a decrease in heart rate and mean arterial
blood pressure reported in dexmedetomidine group, it never
was less than 20% of the baseline values which proved that
the use a-2 agonists provides a hemodynamic stability during
the post-operative periods.
The present work studied the evaluation of adding
dexmedetomidine to low doses of bupivacaine in patients under-
going total knee arthroplasty under combined spinal epidural
anesthesia. More studies including large number of patients
and measurements of efficacy of both, physical therapy and
rehabilitation programs should be performed to confirm our
study findings about the usage of dexmedetomidine as a safe
and effective adjuvant to epidural low volume bupivacaine.
Dose reduction study of local anesthetic on postoperative epidural analgesia 369The study has established that the dose of epidural bupiva-
caine can be safely and significantly lowered by 40% with the
addition of low-dose dexmedetomidine, thereby avoiding
hemodynamic instability and providing an effective post-
operative analgesia, sedation and decreased postoperative
analgesic requirement in patients undergoing total knee
arthroplasty.
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